Axsome Therapeutics, Inc. AXSM
Sales up 65.5%, free cash flow up to -$93.9M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (34, from the latest 10-K and 10-Q)
- EPS (ttm)
- -3.03
- Sales (ttm)
- 865.3M
- Net income (ttm)
- -157.3M
- Sales growth
- +65.5%
- EPS growth
- -
- Sales Q/Q
- +51.9%
- Free cash flow
- -82.6M
- Gross margin
- -
- Oper. margin
- -17.5%
- Net margin
- -18.2%
- FCF margin
- -9.5%
- ROE
- -149.2%
- ROA
- -19.0%
- R&D / sales
- 28.7%
- Dividend
- -
- Debt/Eq
- 1.78
- Curr. ratio
- 1.42
- Cash
- 313.9M
- Op. cash flow (ttm)
- -81.8M
- EBITDA
- -166.3M
- EBITDA margin
- -26.0%
- Net debt
- -125.8M
- Quick ratio
- 1.37
- FCF after stock pay
- -187.6M
- Goodwill / assets
- 1.7%
- Stock pay / sales
- 14.7%
- Shares out.
- 52.6M
- Shares Y/Y
- +3.8%
- Book / share
- 2.00
- Cash / share
- 5.97
- Sales / share
- 16.45
- Asset turnover
- 1.05
- Days sales out.
- 128
- Sales 3Y CAGR
- +134%
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2020 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
- + Shareholders' equity $88.3M
- − Goodwill $12.0M
- − Other intangible assets $40.5M
- = Tangible book value $35.7M
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
AXSM against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics, Inc. | $865.3M | +65.5% | - | -18.2% | -149.2% | -9.5% | 1.78 |
| TGTX TG Therapeutics, Inc. | $897.8M | +87.3% | 82.7% | 11.8% | 18.5% | 9.5% | 1.30 |
| INSP Inspire Medical Systems, Inc. | $880.9M | +13.6% | 86.2% | 11.4% | 12.2% | 11.1% | - |
| SUPN Supernus, Inc. | $865.1M | +8.6% | 87.6% | -5.1% | -4.1% | 10.1% | - |
| IRTC iRhythm Holdings, Inc. | $854.0M | +26.2% | 72.3% | -4.5% | -21.8% | 0.9% | - |
| RGEN Repligen Corp | $805.6M | +16.4% | 53.5% | -1.5% | -0.6% | 13.2% | 0.27 |
Where the $638.5M of revenue came from
by product, year to Dec 31, 2025
- Product Sales $633.8M · 99%
- Royalty and Milestone Revenue $4.7M · 1%
From the segment tables in the 10-K XBRL.
Where the return on equity comes from
DuPont: net margin × asset turnover × leverage, FY2025 against FY2022 · 10-K XBRL, year-end balances
The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.
Profitability
-
Net margin below the peer median-18.2% vs 6.8%
-
Return on equity below 15%-149.2%
-
A profit in 0 of 6 years
Balance sheet
-
Debt larger than equityDebt / equity 1.78 on the latest balance sheet (peer median 0.69)
-
Current assets cover current liabilitiesCurrent ratio 1.42
-
More cash than debtNet cash $125.8M
Cash and shareholders
-
Free cash flow positive in 0 of 6 years−$93.9M last year
-
Share count up over 5 years+33.7%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
$120.0M of principal due, schedule of Sep 30, 2026
Debt
From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
AXSM's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Revenue by product or service
year to Dec 31, 2025| Revenue | Share | vs year before | |
|---|---|---|---|
| Product Sales | 633.8M | 99.3% | +66.1% |
| Royalty and Milestone Revenue | 4.7M | 0.7% | +17.0% |
10-K 0001193125-26-064267, segment and revenue notes (XBRL).
Income statement
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 50.0M | 270.6M | 385.7M | 638.5M |
| Cost of revenue | - | - | - | - | - | - | 5.2M | - | - | - |
| R&D | 21.2M | 20.0M | 23.5M | 53.6M | 70.2M | 58.1M | 57.9M | 97.9M | 187.1M | 183.3M |
| SG&A | 6.3M | 7.2M | 9.4M | 13.6M | 28.9M | 66.6M | 159.3M | 323.1M | 411.4M | 570.6M |
| Operating income | -27.5M | -27.2M | -32.8M | -67.2M | -99.1M | -124.7M | -179.8M | -231.8M | -280.6M | -166.8M |
| Interest expense | 47K | 865K | 772K | 1.3M | 2.1M | 4.6M | -9.7M | -20.0M | -21.6M | -15.9M |
| Pretax income | - | - | - | - | - | -130.4M | -187.1M | -238.3M | -287.1M | -183.7M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 960K | 85K | -530K |
| Net income | -27.2M | -28.9M | -31.0M | -68.3M | -102.9M | -130.4M | -187.1M | -239.2M | -287.2M | -183.2M |
| EPS (diluted) | -1.42 | -1.27 | -1.15 | -2.01 | -2.77 | -3.47 | -4.60 | -5.27 | -5.99 | -3.68 |
| Diluted shares | - | - | - | - | 37.2M | 37.6M | 40.7M | 45.4M | 47.9M | 49.7M |
| Depreciation & amortization | 20K | 43K | 49K | 37K | 24K | 76K | 263K | 459K | 532K | 503K |
| EBITDA | -27.5M | -27.1M | -32.8M | -67.2M | -99.1M | -124.6M | -179.5M | -231.4M | -280.0M | -166.3M |
| Operating margin | - | - | - | - | - | - | -359.3% | -85.7% | -72.7% | -26.1% |
| Net margin | - | - | - | - | - | - | -374.0% | -88.4% | -74.5% | -28.7% |
| Revenue growth | - | - | - | - | - | - | - | +441% | +42.5% | +65.5% |
Balance sheet
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | - | - | - | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 315.4M | 322.9M |
| Receivables | - | - | - | - | - | - | 37.7M | 94.8M | 142.0M | 224.5M |
| Inventory | - | - | - | - | - | - | 4.3M | 15.1M | 15.7M | 27.9M |
| Current assets | 38.0M | 35.3M | 15.2M | 220.4M | 184.0M | 86.5M | 245.6M | 504.3M | 485.1M | 589.0M |
| Property & equipment | 101K | 68K | 52K | 31K | 53K | 284K | 722K | 846K | 584K | 562K |
| Goodwill | - | - | - | - | - | - | 10.3M | 12.0M | 12.0M | 12.0M |
| Other intangible assets | - | - | - | - | - | - | 59.7M | 53.3M | 46.9M | 40.5M |
| Total assets | 38.2M | 35.6M | 15.4M | 220.5M | 186.1M | 87.8M | 331.5M | 588.2M | 568.5M | 689.8M |
| Accounts payable | 4.1M | 3.4M | 3.7M | 10.9M | 13.5M | 13.1M | 38.6M | 40.7M | 72.0M | 65.5M |
| Current liabilities | 7.2M | 12.2M | 10.8M | 24.5M | 23.4M | 23.1M | 96.6M | 138.9M | 230.1M | 378.8M |
| Total debt | 9.7M | 9.9M | 6.9M | 19.9M | 48.3M | 49.1M | 94.3M | 178.1M | 180.7M | 187.7M |
| Total liabilities | 16.6M | 18.8M | 14.4M | 41.8M | 72.3M | 72.2M | 221.9M | 397.3M | 511.5M | 601.5M |
| Shareholders' equity | 21.6M | 16.7M | 938K | 178.7M | 113.8M | 15.6M | 109.6M | 191.0M | 57.0M | 88.3M |
| Retained earnings | -47.6M | -76.6M | -107.6M | -175.9M | -278.8M | -409.2M | -596.3M | -835.6M | -1.1B | -1.3B |
Cash flow
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -21.3M | -26.5M | -30.1M | -46.4M | -78.5M | -108.2M | -116.5M | -145.1M | -128.4M | -93.4M |
| Capital spending | 105K | 10K | 33K | 16K | 46K | 308K | 702K | 582K | 270K | 480K |
| Free cash flow | -21.4M | -26.5M | -30.1M | -46.4M | -78.5M | -108.5M | -117.2M | -145.7M | -128.7M | -93.9M |
| Stock-based pay (added back) | 2.0M | 2.1M | 1.8M | 6.1M | 14.8M | 20.8M | 37.7M | 62.6M | 85.2M | 93.8M |
| Free cash flow after stock pay | -23.4M | -28.6M | -31.8M | -52.5M | -93.3M | -129.3M | -154.9M | -208.3M | -213.9M | -187.6M |
| Acquisitions | - | - | - | - | - | - | 53.0M | - | - | - |
| Debt raised | 10.0M | - | - | 20.0M | 50.0M | - | - | - | - | - |
| Debt repaid | - | 278K | 3.3M | 7.2M | 21.7M | - | - | - | - | 332.0M |
| Investing cash flow | -105K | -10K | -33K | -16K | -46K | -308K | -53.7M | -582K | -270K | -480K |
| Financing cash flow | 10.0M | 23.9M | 10.0M | 252.4M | 42.4M | 11.1M | 284.6M | 331.0M | 57.8M | 101.5M |
Stock-based pay and leases
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 2.0M | 2.1M | 1.8M | 6.1M | 14.8M | 20.8M | 37.7M | 62.6M | 85.2M | 93.8M |
| Stock-based pay / revenue | - | - | - | - | - | - | 75.4% | 23.1% | 22.1% | 14.7% |
| Operating lease cost | - | - | - | - | 48K | 1.1M | 1.2M | 2.2M | 2.3M | 4.7M |
| Finance lease principal paid | - | - | - | - | - | - | - | - | 990K | 2.1M |
| Right-of-use assets | - | - | - | - | 1.7M | 660K | 420K | 6.8M | 5.4M | 20.9M |
| Operating lease liabilities | - | - | - | - | 1.8M | 621K | 425K | 8.3M | 7.9M | 23.6M |
| Finance lease liabilities | - | - | - | - | - | - | - | - | 4.4M | 6.8M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AXSM/export.csv") into a cell.